Antibodies for bioanalysis and drug monitoring of ipilimumab

Develop highly selective and sensitive PK and ADA assays for the immune checkpoint inhibitor drug ipilimumab (Yervoy) using our range of ready-made anti-idiotypic antibodies.

  • Highly specific to ipilimumab or the ipilimumab-CTLA-4 complex
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch to batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Ipilimumab.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Ipilimumab Inhibitory

Type 1

HCA330

AbD34433

Fab-FSx21

0.3

PK bridging ELISA

Order HCA330

HCA329
HCA329P

AbD34429ia

Human IgG1

HRP

1

PK bridging ELISA

ADA control

Order HCA329
Order HCA329P

HCA327

AbD34283ia

Human IgG1

16

ADA control

Order HCA327

HCA328

AbD34428ia

Human IgG1

0.3

ADA control

Order HCA328

Ipilimumab-CTLA-4 Complex Specific
Type 3

HCA331

AbD34294

Fab-FSx21

252

PK ELISA antigen capture format

Order HCA331

TZA001

AbD34294ad

Fab-F-Spy2-H

252

PK ELISA antigen capture format

Order TZA001

TZA001P

AbD34294pap

Fab2-FH-X22-HRP

252

PK ELISA antigen capture format

Order TZA001P

*Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody with DYKDDDDK (F) and StrepX-StrepX (Sx2) tags
2 Monovalent Fab antibody with DYKDDDDK (F), SpyTag version 2 (Spy2) and His6 (H) tags
3 Bivalent Fab antibody generated by coupling TZA001 (AbD34294ad) with HRP conjugated BiSpyCatcher2 (TZC002)


Anti-Ipilimumab Inhibitory Antibodies (Type 1)

Type 1 anti-ipilimumab antibodies inhibit the binding of the drug ipilimumab to its target, cytotoxic T lymphocyte-associated antigen 4 (CTLA-4). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are available in three different affinities, and are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.

Anti-Ipilimumab-CTLA-4 Complex Specific Antibody (Type 3)

The Type 3 antibody specifically recognizes the drug-target complex, detecting ipilimumab only when it is bound to CTLA-4. It is suitable as a detection antibody in a PK antigen capture assay, as an alternative assay format to the bridging ELISA. Clone AbD34294 is available in three formats:

  • TZA001P is an HRP conjugated bivalent Fab antibody for use in a direct ELISA (Figure 2); the antibody has been made using SpyTag technology by coupling TZA001 to HRP conjugated BiSpyCatcher2. A bivalent detection antibody leads to higher assay sensitivity. Coupling to BiCatcher with site-specifically attached HRP ensures high batch-to-batch consistency
  • TZA001 is a monovalent Fab antibody with a SpyTag2 that can be coupled to a range of SpyCatcher products using SpyTag technology; this enables switching between monovalent, bivalent, and Ig-like formats, and site-specific conjugation to a label of choice using SpyCatcher2-Cys (TZC001CYS), BiSpyCatcher2-Cys (TZC002CYS), or BiSpyCatcher2-CYS3 (TZC002CYS3) products
  • HCA331 is a monovalent Fab antibody for development of an indirect ELISA using an anti-DYKDDDDK antibody for detection (Figure 3)

ELISA Protocols to Get You Started

PK Bridging ELISA

Fig. 1. Ipilimumab PK bridging ELISA using antibodies HCA330 and HCA329P.

Fig. 1. Ipilimumab PK bridging ELISA using antibodies HCA330 and HCA329P.

Schematic image of PK bridging ELISA measuring free drug

Schematic image of PK bridging ELISA measuring free drug. Anti-idiotypic capture antibody, Fab format (purple), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format (blue), labeled with HRP.


PK Antigen Capture ELISA

Fig. 2. Ipilimumab PK antigen capture ELISA using antibody TZA001P.

Fig. 2. Ipilimumab PK antigen capture ELISA using antibody TZA001P.

Schematic image of PK antigen capture ELISA.

Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, Fab2 antibody (purple), and BiSpyCatcher2 (gray) labeled with HRP (orange).


Fig. 3. Ipilimumab PK antigen capture ELISA using antibody HCA331.

Fig. 3. Ipilimumab PK antigen capture ELISA using antibody HCA331.

Schematic image of PK antigen capture ELISA

Schematic image of PK antigen capture ELISA. Drug target (red), monoclonal antibody drug (gold), drug-target complex detection antibody, monovalent Fab format (purple), anti-tag detection antibody labeled with HRP (gray).


ADA Bridging ELISA

Fig. 4. Ipilimumab ADA bridging ELISA using antibody HCA327, HCA328 or HCA329.

Fig. 4. Ipilimumab ADA bridging ELISA using antibody HCA327, HCA328, or HCA329.

Schematic image of ADA bridging assay

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).


Related Product



Resources



Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.